They inject for the first time an experimental virus that kills cancer

The goal is for it to treat advanced solid tumor cancers along with other therapies.


Courtesy | The virus has been shown to reduce the size of tumors in colon, lung, breast, ovarian and pancreatic cancer.

The CF33-hNIS virus, also called ‘Vaxinia’, which was created by researchers at the City of Hope National Medical Center in California, United States, and which manages to reduce only cancer cells, has been injected for the first time.

The great advantage of this virus is that an oncolytic virus prefers to attack and infect tumor cells, so success is greater. The virus amplifies the body’s immune response to cancer. The goal is for it to treat advanced solid tumor cancers along with other therapies.

Reduces five cancers

According to the results of the first animal tests and several laboratory experiments, the virus has been shown to reduce the size of tumors in the case of colon, lung, breast, ovarian and pancreatic cancer.

For the trial to move forward and be completed and achieve great results, we must wait until 2025. The next step now is for Vaxinia to be approved in a Phase I trial of 100 cancer patients with advanced or metastatic solid tumors that were previously have tried at least two other treatments.

A first injected patient

City of Hope and immuno-oncology company Imugene Limited announced a few days ago that the first patient had already received the first dose in a Phase 1 clinical trial evaluating the safety of the new cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

“Our previous research showed that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to respond better to other immunotherapies, including checkpoint inhibitors,” said Daneng Li, the principal investigator and professor in the Department of Medical Oncology and Therapeutic Research. “Now is the time to further enhance the power of immunotherapy and we believe that CF33-hNIS has the potential to improve outcomes for our patients in their battle against cancer.”

Have the information instantly on your cell phone. Join the Diario Primicia group on WhatsApp through the following link:https://chat.whatsapp.com/F8uA0zT8ho4ChOprPUU6lh

We are also on Telegram as @DiarioPrimicia, join us here: https://t.me/diarioprimicia

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.